Literature DB >> 1909733

Human IgA and IgG F(ab')2 that bind to staphylococcal protein A belong to the VHIII subgroup.

E H Sasso1, G J Silverman, M Mannik.   

Abstract

Staphylococcal protein A (SPA) is a bacterial membrane protein that possesses, in addition to its Fc gamma-binding activity, a distinct specificity for the Fab region of some IgM, IgA, IgG, and IgE. The Fab site that binds to SPA has been localized to the V region of the Ig H chain. In a previous study of human monoclonal and polyclonal IgM, we demonstrated that binding to SPA was highly restricted to molecules of the VHIII subgroup, and that nearly all VHIII IgM were able to bind SPA. The present study examines the VH composition of SPA-binding and SPA-nonbinding fractions of purified human polyclonal IgA, and IgG F(ab')2 fragments. We found that 22% of the IgA and 15% of the IgG F(ab')2 bound to SPA-agarose. Analysis with VH subgroup-specific antisera indicated that the SPA-binding fraction of IgA was dominated by the VHIII subgroup, and the SPA-binding fraction of IgG F(ab')2 contained only VHIII molecules. Furthermore, substantial portions of the total VHIII protein in IgA and in IgG F(ab')2 bound to SPA. We conclude that Fab binding to SPA is both restricted to and highly prevalent among human VHIII molecules, regardless of Ig class. These results suggest that protein A is an Ig superantigen.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1909733

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  53 in total

1.  Crystal structure of a Staphylococcus aureus protein A domain complexed with the Fab fragment of a human IgM antibody: structural basis for recognition of B-cell receptors and superantigen activity.

Authors:  M Graille; E A Stura; A L Corper; B J Sutton; M J Taussig; J B Charbonnier; G J Silverman
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

2.  Interactions between a single immunoglobulin-binding domain of protein L from Peptostreptococcus magnus and a human kappa light chain.

Authors:  J A Beckingham; S P Bottomley; R Hinton; B J Sutton; M G Gore
Journal:  Biochem J       Date:  1999-05-15       Impact factor: 3.857

3.  By-passing selection: direct screening for antibody-antigen interactions using protein arrays.

Authors:  L J Holt; K Büssow; G Walter; I M Tomlinson
Journal:  Nucleic Acids Res       Date:  2000-08-01       Impact factor: 16.971

4.  Specific in vivo deletion of B-cell subpopulations expressing human immunoglobulins by the B-cell superantigen protein L.

Authors:  Muriel Viau; Nancy S Longo; Peter E Lipsky; Lars Björck; Moncef Zouali
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

Review 5.  B cell superantigens: a microbe's answer to innate-like B cells and natural antibodies.

Authors:  Carl S Goodyear; Gregg J Silverman
Journal:  Springer Semin Immunopathol       Date:  2005-03

6.  Synthetic effects of secG and secY2 mutations on exoproteome biogenesis in Staphylococcus aureus.

Authors:  Mark J J B Sibbald; Theresa Winter; Magdalena M van der Kooi-Pol; G Buist; E Tsompanidou; Tjibbe Bosma; Tina Schäfer; Knut Ohlsen; Michael Hecker; Haike Antelmann; Susanne Engelmann; Jan Maarten van Dijl
Journal:  J Bacteriol       Date:  2010-05-14       Impact factor: 3.490

7.  B cell development in GALT: role of bacterial superantigen-like molecules.

Authors:  Kari M Severson; Michael Mallozzi; Adam Driks; Katherine L Knight
Journal:  J Immunol       Date:  2010-05-07       Impact factor: 5.422

8.  Staphylococcus aureus Cowan I-induced human immunoglobulin responses: preferential IgM rheumatoid factor production and VH3 mRNA expression by protein A-binding B cells.

Authors:  L M Kozlowski; S R Kunning; Y Zheng; L M Wheatley; A I Levinson
Journal:  J Clin Immunol       Date:  1995-05       Impact factor: 8.317

9.  Analysis of human antitopoisomerase-I idiotypes.

Authors:  D Vazquez-Abad; V Pascual; M Zanetti; N F Rothfield
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

10.  Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis.

Authors:  Kathrin Schwager; Manuela Kaspar; Frank Bootz; Roberto Marcolongo; Erberto Paresce; Dario Neri; Eveline Trachsel
Journal:  Arthritis Res Ther       Date:  2009-09-25       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.